PharmaMedium impactPre-market

Brokerages bullish on Divi’s Laboratories after Q3 results

13 Feb 2026 · 07:03 ISTpre-market1 source ↓written by the desknot a recommendation

to ₹2: 45%
to ₹6: 4%

Analysts have mixed views on Divi’s Laboratories following its Q3FY26 results. The company reported net profit ₹583 cr, down from ₹696 cr sequentially, impacted by one-time expenses ₹74 cr. Brokerages see an upside of 45% to ₹2,854 from the current price of ₹6,286.45, with a downside of 4% to ₹6,050.

Not investment advice. For informational purposes only.

OI Charts is not a SEBI-registered investment adviser or research analyst. This bulletin was written by the OI Charts desk from the public sources listed here. It is commentary on market conditions, not a basis for any investment decision and not a recommendation to buy or sell any security. Prices as of 13 Feb 2026, 07:03 IST.

Sourcesnews.google.com

DIVISLABS
Pharma

Read inEN हिं తె मरा த ગુ

24 MayDivi’s Labs Q4 net profit rises 13% to ₹751 crMediumDivi’s Laboratories reported a 13% rise in Q4 net profit to ₹751 crore, driven by total income of ₹2,986 crore. The company declared a ₹30 dividend, reflecting strong financial performance.
24 MayDivi's Laboratories Q4 net profit rises 13% YoYMediumDivi's Laboratories reported a consolidated net profit of ₹751 crore for Q4, a 13% YoY increase. Revenue rose 10% to ₹2,831 crore, and a final dividend of ₹30 per share was proposed, subject to AGM approval.
1 OctAjanta Pharma promoters pledge shares for ₹3,873 crore debtMediumAjanta Pharma's promoters pledged 26,21,067 shares to secure ₹3,873 crore in debt instruments, comprising ₹3,373 crore from Lenexis Foodworks and ₹500 crore from Inspira Realty 2. This move may affect liquidity and investor sentiment.
29 SeptAnupam Rasayan completes Bliss GVS Pharma acquisitionHighAnupam Rasayan India has acquired a 48.2% stake in Bliss GVS Pharma at ₹299 per share, funded by a ₹300 crore loan and ₹1,450 crore from investors. This strategic move enhances its portfolio in pharmaceuticals.
29 SeptNifty 50 declines as bond yields rise and risks escalateHighThe Nifty 50 closed at 22,780.25, down 1.56%, as 10-year G-Sec yields rose to 7.17%. The index remains below its 50-day SMA, indicating weak momentum amid geopolitical risks and potential RBI rate hikes.
29 SeptStocks poised to gain from falling rupeeMediumAs the rupee depreciates, Indian stocks with foreign revenue streams may benefit. Indegene is highlighted for its potential in the life sciences sector, capitalizing on the current market stress driven by oil prices and geopolitical risks.

Brokerages bullish on Divi’s Laboratories after Q3 results

Related